Next Article in Journal
The NMD Pathway Regulates GABARAPL1 mRNA during the EMT
Previous Article in Journal
Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
 
 
Review

Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications

1
Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego Street 49, 60-355 Poznan, Poland
2
Institute of Human Genetics, Polish Academy of Sciences Poznan, Strzeszynska Street 32, 60-479 Poznan, Poland
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Giuseppina Basta
Biomedicines 2021, 9(10), 1301; https://doi.org/10.3390/biomedicines9101301
Received: 9 August 2021 / Revised: 7 September 2021 / Accepted: 15 September 2021 / Published: 23 September 2021
(This article belongs to the Section Molecular and Translational Medicine)
Sarcopenia, which is a decrease in muscle strength and quality of muscle tissue, is a common disorder among patients suffering from inflammatory bowel disease. This particular group of patients often presents with malnutrition and shows low physical activity, which increases the risk of sarcopenia. Another important factor in the development of sarcopenia is an imbalanced ratio of myostatin and follistatin, which may stem from inflammation as well as genetic factors. Currently, research in this area continues, and is aimed at identifying an effective medication for the treatment of this condition. Additionally, we still have no sarcopenia markers that can be used for diagnosis. In this paper, we address the role of myostatin and follistatin as potential markers in the diagnosis of sarcopenia in patients with Crohn’s disease and ulcerative colitis, particularly in view of the genetic and biological aspects. We also present data on new perspectives in the pharmacotherapy of sarcopenia (i.e., myostatin inhibitors and gene therapy). Nevertheless, knowledge is still scarce about the roles of follistatin and myostatin in sarcopenia development among patients suffering from inflammatory bowel disease, which warrants further study. View Full-Text
Keywords: sarcopenia; IBD; myostatin; follistatin sarcopenia; IBD; myostatin; follistatin
Show Figures

Figure 1

MDPI and ACS Style

Skrzypczak, D.; Skrzypczak-Zielińska, M.; Ratajczak, A.E.; Szymczak-Tomczak, A.; Eder, P.; Słomski, R.; Dobrowolska, A.; Krela-Kaźmierczak, I. Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. Biomedicines 2021, 9, 1301. https://doi.org/10.3390/biomedicines9101301

AMA Style

Skrzypczak D, Skrzypczak-Zielińska M, Ratajczak AE, Szymczak-Tomczak A, Eder P, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. Biomedicines. 2021; 9(10):1301. https://doi.org/10.3390/biomedicines9101301

Chicago/Turabian Style

Skrzypczak, Dorota, Marzena Skrzypczak-Zielińska, Alicja Ewa Ratajczak, Aleksandra Szymczak-Tomczak, Piotr Eder, Ryszard Słomski, Agnieszka Dobrowolska, and Iwona Krela-Kaźmierczak. 2021. "Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications" Biomedicines 9, no. 10: 1301. https://doi.org/10.3390/biomedicines9101301

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop